ACM
VIR icon

Anfield Capital Management’s Vir Biotechnology VIR Stock Holding History

Anfield Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-667
Closed -$16.9K – 91
2022
Q4 		$16.9K Sell
667
-123
-16% -$3.02K 0.01% 81
2022
Q3 		$15K Buy
790
+28
+4% +$712 0.01% 87
2022
Q2 		$19K Buy
762
+112
+17% +$2.62K 0.01% 90
2022
Q1 		$17K Buy
+650
New +$19.3K 0.01% 94

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Anfield Capital Management's VIR Position: Q1 2023 in Review

Anfield Capital Management sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 667 shares — an estimated $16.9K sold.

Anfield Capital Management first reported a position in VIR in Q1 2022 and held it in 4 quarters. The position peaked at $19K in Q2 2022. 231 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Anfield Capital Management reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Anfield Capital Management sold 667 Vir Biotechnology shares in Q1 2023, an estimated $16.9K.
  • Anfield Capital Management first reported a position in Vir Biotechnology in Q1 2022 and held it in 4 quarters.
  • Anfield Capital Management's Vir Biotechnology position peaked at $19K in Q2 2022.
  • 231 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.